Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ivy Rx vs Midi Health

Ivy Rx
Graded #189

Higher grade

vs+10.100000000000001
Midi Health
Graded #414

Lower grade

The verdict

Ivy Rx takes it — 66.5/100 to 56.4/100.

Ivy Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth provider offering tiered compounded semaglutide and tirzepatide programs.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueIvy Rx +16
61
45
Dose & formulationIvy Rx +24
64
40
Clinical oversightIvy Rx +4
82
78
Labs & monitoringIvy Rx +1
53
52
FulfillmentIvy Rx +3
81
78
Contract termsEven
55
55
Ivy Rx · left barMidi Health · right bar

The numbers

MetricIvy RxMidi Health
WeighScore66.5/10056.4/100
GradeCC
Scorecard rank#189#414
Semaglutide$175/mo (starting dose, compounded)Not disclosed
Tirzepatide$275/mo (starting dose, compounded)Not disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Ivy Rx

Graded #189 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
Midi Health

Graded #414 · C

Strengths

  • Available in all 50 states
  • Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
  • Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
  • Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)

Where it loses points

  • Does not accept Medicare, Medicaid, or Medi-Cal
  • GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
  • Menopause-focused — not the right fit for men or younger women whose main goal is weight loss

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard